US 2012/0040384 A1 · LYOPHILISED DABIGATRAN

Abstract

The invention relates to a lyophilised form of dabigatran of formula (I) its use as a calibrator in the assays for the determination of pharmacodinamic effects of dabigatran etexilate as well as such assays per se. In the preparation of the lyophilised standards, dabigatran is dissolved in an aqueous acidic solution before freeze-drying.

Claims18

Dependent claims

Process for the manufacture of lyophilised dabigatran of formula I

comprising the steps of dissolving dabigatran in aqueous acidic solution, adding the solution to human anticoagulated plasma and freeze-drying the thus obtained solution.

Dependencies are inferred from the claim text.

Facts

Application

13/147,242Filed 27 Jan 2010

Priority

EP 09151865.42 Feb 2009

Published

16 Feb 2012

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

C12Q 1/56
Measuring or testing processes involving enzymes, nucleic acids or microorganisms ; Compositions therefor; Processes of preparing such…
A61K 9/19
Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles: lyophilised , i.e.…
A61K 31/4439
Containing further heterocyclic ring systems: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 7/02
Drugs for disorders of the blood or the extracellular fluid: antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

Claims18

Dependent claims

Process for the manufacture of lyophilised dabigatran of formula I

comprising the steps of dissolving dabigatran in aqueous acidic solution, adding the solution to human anticoagulated plasma and freeze-drying the thus obtained solution.

Dependencies are inferred from the claim text.

Lyophilised dabigatran

Life of this patent

Abstract

Claims18

Lyophilised dabigatran

Life of this patent

Abstract

Claims18